Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients.
CSF
DIPG
HGG
cfDNA
ctDNA
plasma
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
25
6
2021
pubmed:
26
6
2021
medline:
26
6
2021
Statut:
epublish
Résumé
The use of liquid biopsy is of potential high importance for children with high grade (HGG) and diffuse midline gliomas (DMG), particularly where surgical procedures are limited, and invasive biopsy sampling not without risk. To date, however, the evidence that detection of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) could provide useful information for these patients has been limited, or contradictory. We optimized droplet digital PCR (ddPCR) assays for the detection of common somatic mutations observed in pediatric HGG/DMG, and applied them to liquid biopsies from plasma, serum, cerebrospinal fluid (CSF), and cystic fluid collected from 32 patients. Although detectable in all biomaterial types, ctDNA presented at significantly higher levels in CSF compared to plasma and/or serum. When applied to a cohort of 127 plasma specimens from 41 patients collected from 2011 to 2018 as part of a randomized clinical trial in pediatric non-brainstem HGG/DMG, ctDNA profiling by ddPCR was of limited use due to the small volumes (mean = 0.49 mL) available. In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in Tumor-specific DNA alterations are more readily detected in CSF than plasma. Although we demonstrate the potential of the approach to assessing tumor burden, our results highlight the necessity for adequate sample collection and approach to improve detection if plasma samples are to be used.
Sections du résumé
BACKGROUND
BACKGROUND
The use of liquid biopsy is of potential high importance for children with high grade (HGG) and diffuse midline gliomas (DMG), particularly where surgical procedures are limited, and invasive biopsy sampling not without risk. To date, however, the evidence that detection of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) could provide useful information for these patients has been limited, or contradictory.
METHODS
METHODS
We optimized droplet digital PCR (ddPCR) assays for the detection of common somatic mutations observed in pediatric HGG/DMG, and applied them to liquid biopsies from plasma, serum, cerebrospinal fluid (CSF), and cystic fluid collected from 32 patients.
RESULTS
RESULTS
Although detectable in all biomaterial types, ctDNA presented at significantly higher levels in CSF compared to plasma and/or serum. When applied to a cohort of 127 plasma specimens from 41 patients collected from 2011 to 2018 as part of a randomized clinical trial in pediatric non-brainstem HGG/DMG, ctDNA profiling by ddPCR was of limited use due to the small volumes (mean = 0.49 mL) available. In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in
CONCLUSION
CONCLUSIONS
Tumor-specific DNA alterations are more readily detected in CSF than plasma. Although we demonstrate the potential of the approach to assessing tumor burden, our results highlight the necessity for adequate sample collection and approach to improve detection if plasma samples are to be used.
Identifiants
pubmed: 34169282
doi: 10.1093/noajnl/vdab013
pii: vdab013
pmc: PMC8218704
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab013Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Clin Cancer Res. 2016 Nov 15;22(22):5564-5573
pubmed: 27440268
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
JCO Precis Oncol. 2018;2018:
pubmed: 30027144
CNS Oncol. 2019 Jun;8(2):CNS34
pubmed: 30855176
Acta Neuropathol Commun. 2018 Aug 15;6(1):80
pubmed: 30111355
Nat Genet. 1998 Feb;18(2):184-7
pubmed: 9462753
Int J Cancer. 2019 Jan 1;144(1):68-79
pubmed: 29923174
Clin Cancer Res. 2020 Apr 15;26(8):1856-1865
pubmed: 31924736
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859
pubmed: 30322880
AJNR Am J Neuroradiol. 2019 Mar;40(3):568-575
pubmed: 30819765
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819
pubmed: 29615461
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Eur J Cancer. 2019 Nov;121:224-235
pubmed: 31543384
Nat Med. 2020 Jul;26(7):1044-1047
pubmed: 32572265
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Neuro Oncol. 2018 Oct 9;20(11):1547-1555
pubmed: 29741745
J Clin Oncol. 2019 Jun 20;37(18):1547-1557
pubmed: 31059311
J Clin Oncol. 2018 Apr 1;36(10):951-958
pubmed: 29412784
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Sci Rep. 2020 Feb 25;10(1):3391
pubmed: 32099048
JCO Precis Oncol. 2018;2:
pubmed: 32832832
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
Oncotarget. 2017 Dec 6;8(67):112036-112050
pubmed: 29340109
J Neurosurg Pediatr. 2017 Sep;20(3):261-268
pubmed: 28621573
Front Oncol. 2019 Oct 02;9:947
pubmed: 31632903
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Cancer Discov. 2020 Jul;10(7):942-963
pubmed: 32238360
Clin Chem. 2019 Nov;65(11):1405-1413
pubmed: 31551314
Neuro Oncol. 2017 Jul 1;19(7):986-996
pubmed: 28104717
Neuro Oncol. 2020 Jan 11;22(1):116-127
pubmed: 31419298
Clin Cancer Res. 2011 Jul 15;17(14):4790-8
pubmed: 21610142
Cancer Med. 2015 Apr;4(4):540-50
pubmed: 25653133
Acta Neuropathol Commun. 2017 Apr 17;5(1):28
pubmed: 28416018
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Clin Cancer Res. 2016 Dec 1;22(23):5772-5782
pubmed: 27601595
Clin Cancer Res. 2016 Sep 1;22(17):4356-65
pubmed: 27283964
Cancer. 2016 Oct;122(19):3015-23
pubmed: 27351911
J Neurooncol. 2016 May;128(1):93-100
pubmed: 26961773